Dutasteride for the treatment of benign prostatic hyperplasia

  title={Dutasteride for the treatment of benign prostatic hyperplasia},
  author={C. Wu and A. Kapoor},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1399 - 1408}
  • C. Wu, A. Kapoor
  • Published 2013
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms that greatly affect quality of life. Dutasteride is a selective inhibitor of type 1 and type 2 isoforms of 5-α-reductase, an enzyme responsible for the conversion of testosterone to 5-α-dihydrotestosterone, approved as a treatment for symptomatic BPH. Areas covered: This article will cover the… CONTINUE READING
    15 Citations
    Effects of dutasteride on serum free‐testosterone and clinical significance of testosterone changes
    • 3
    • Highly Influenced
    Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.
    • 13
    • PDF
    Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement
    • T. Maeda, E. Kikuchi, +7 authors M. Oya
    • Medicine
    • International journal of urology : official journal of the Japanese Urological Association
    • 2018
    • 4
    Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
    • Jamal Shamsara
    • Computer Science, Medicine
    • Interdisciplinary Sciences: Computational Life Sciences
    • 2018
    • 1


    The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    • 546
    • Highly Influential
    The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    • 1,610
    • PDF
    The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia
    • 51
    • PDF
    5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    • R. Rittmaster
    • Medicine
    • Best practice & research. Clinical endocrinology & metabolism
    • 2008
    • 54
    [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    • 51
    Benign prostatic hyperplasia: an overview.
    • 224
    • Highly Influential
    Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
    • 635
    • Highly Influential